Banco Santander S.A. Has $1.50 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Banco Santander S.A. lessened its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 54.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 172,231 shares of the biopharmaceutical company's stock after selling 205,137 shares during the quarter. Banco Santander S.A. owned 0.11% of Ocular Therapeutix worth $1,498,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Atlas Capital Advisors LLC bought a new position in Ocular Therapeutix during the 2nd quarter worth $34,000. Amalgamated Bank grew its holdings in shares of Ocular Therapeutix by 37.9% during the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 1,015 shares during the period. Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix in the third quarter valued at about $70,000. Finally, Algert Global LLC bought a new stake in Ocular Therapeutix during the second quarter worth about $69,000. Institutional investors own 59.21% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright raised their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, November 15th. Robert W. Baird decreased their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Finally, Scotiabank started coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded up $0.31 during midday trading on Friday, reaching $8.83. 819,876 shares of the company were exchanged, compared to its average volume of 947,681. The stock's 50-day moving average price is $9.90 and its 200-day moving average price is $8.11. The stock has a market cap of $1.39 billion, a P/E ratio of -6.69 and a beta of 1.26. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a one year low of $2.14 and a one year high of $11.77.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.